Effect of pazufloxacin mesilate, a new quinolone antibacterial agent, for intravenous use on QT interval
Fukuda, H.; Morita, Y.; Shiotani, N.; Mizuo, M.; Komae, N.
Japanese Journal of Antibiotics 57(4): 404-412
2004
ISSN/ISBN: 0368-2781 PMID: 15535041 Document Number: 582781
The potential for QT interval prolongation of pazufloxacin mesilate (PZFX mesilate), a new quinolone antibacterial agent for intravenous use, was investigated by in vitro and in vivo electrophysiology studies. Following results were obtained. In vitro electrophysiology study using guinea pig papillary muscles: PZFX mesilate (30300 M) had no effects on resting membrane potential (RMP), action potential amplitude (APA) and action potential duration (APD). Reference quinolones, sparfloxacin (3 30 M) and moxifloxacin (10apprx100 muM), had no effects on RMP and APA, but significantly prolonged APD at more than 3 and 10 muM, respectively, while ciprofloxacin (10apprx100 muM) had no effect on each parameter. In vivo electrophysiology study using anesthetized dogs: PZFX mesilate had no effects on electrocardiograph parameter (PR interval, QRS interval, QT interval and QTc) after intravenous administration of 3apprx30 mg/kg. These results suggest that PZFX mesilate has low potential for QT interval prolongation.